Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Nicole DeFeudis

Editor

Just five months after closing its $2.9 billion deal for MorphoSys, Novartis has recorded an $800 million impairment on the acquisition after a review of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Nicole DeFeudis

Editor

Sign up to read this article for free.

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

Nicole DeFeudis

Editor

Sign up to read this article for free.

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat